Previous Close | 6.09 |
Open | 6.04 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's Range | 5.76 - 6.09 |
52 Week Range | 2.36 - 7.99 |
Volume | |
Avg. Volume | 341,788 |
Market Cap | 337.892M |
Beta (5Y Monthly) | 1.14 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.11 |
Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.88 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALDX
Insiders who bought Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) in the last 12 months may probably not pay attention to...
LEXINGTON, Mass., December 21, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629. Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure. ADX-629 and placebo were well tolerated, and no safety concerns were noted. Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision D